EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Intravesical mitomycin-C administered immediately before transurethral resection of bladder tumor in non–muscle-invasive bladder cancer: Clinical outcomes and molecular predictors from over 3 years of extended follow-up in a phase II trial

Hye Won Lee iD, Geehyun Song iD, Hyung Ho Lee iD, Eui Hyun Jung iD, Seo-Young Kim iD, Hanbyeol Kim iD, Weon Seo Park iD, Joonha Kwon iD, Ho Kyung Seo iD

Investigative and Clinical Urology · 2026

DOI: 10.4111/icu.20260135 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Investigative and Clinical Urology, 2026. Verfasst von Hye Won Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Antibiotics, Antineoplastic, Mitomycin, Neoplasm Recurrence, Local, Non-Muscle Invasive Bladder Neoplasms. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCC, National Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To evaluate the long-term outcomes and molecular correlates of response after immediate preoperative intravesical chemotherapy (IPeIC) with mitomycin-C (MMC) in patients with non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: In this single-center, open-label, randomized phase II trial, 33 patients received two split doses of IPeIC/MMC (40 mg/20 mL), whereas 38 patients underwent transurethral resection of bladder tumor (TURBT) alone. The primary endpoint was 3-year recurrence-free survival (RFS), and secondary endpoints included progression-free survival (PFS). Exploratory RNA sequencing was performed on IPeIC-treated patients (three with recurrence, 25 without) using a Monte Carlo-based resampling strategy. RESULTS: The median follow-up durations were comparable between the intervention (60.0 months) and control arms (60.4 months). IPeIC/MMC reduced recurrence risk by 76.8% versus TURBT alone (p=0.024), yielding a 3-year RFS rate of 90.7% versus 78.6%. On multivariable analysis, IPeIC/MMC independently improved RFS (hazard ratio [HR] 0.266, p=0.044). IPeIC was associated with superior PFS, with 3-year and 5-year rates of 100% versus 92.1% and 85.8%, respectively, in the controls (HR 0.078, p=0.014). Exploratory transcriptomics identified low Glutathione S-transferase Mu 1 (GSTM1) expression as the factor most strongly associated with recurrence. CONCLUSIONS: IPeIC/MMC is associated with improved long-term oncological outcomes compared with TURBT alone and represents a safe prophylactic option for patients with NMIBC who are unable to receive standard immediate postoperative intravesical chemotherapy because of safety concerns or practical constraints. The GSTM1 findings are hypothesis-generating and support future biomarker-driven validation studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibiotics, AntineoplasticMitomycinNeoplasm Recurrence, LocalNon-Muscle Invasive Bladder NeoplasmsAgedFemaleHumansMaleMiddle AgedAdministration, IntravesicalFollow-Up StudiesNeoadjuvant TherapyTransurethral Resection of BladderTreatment Outcome

Stichwörter der Autor:innen

BiomarkersMitomycin-CNeoadjuvant therapyNon-muscle-invasive bladder cancerSequence analysis

Substanzen

Antibiotics, AntineoplasticMitomycin

Autor:innen und Institutionen

  • Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea.
  • Biostatistics Collaboration Team, Research Institute, National Cancer Center, Goyang, Korea.
  • Bioinformatics Branch, National Cancer Center, Goyang, Korea.
  • Department of Pathology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea.
  • Department of Public Health & AI, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.

ORCID-Profile: Hye Won Lee, Geehyun Song, Hyung Ho Lee, Eui Hyun Jung, Seo-Young Kim, Hanbyeol Kim, Weon Seo Park, Joonha Kwon, Ho Kyung Seo

Förderung

  • NCC
  • National Cancer Center

Zitieren

APA

Lee, H. W., Song, G., Lee, H. H., Jung, E. H., Kim, S. Y., Kim, H., Park, W. S., Kwon, J., & Seo, H. K. (2026). Intravesical mitomycin-C administered immediately before transurethral resection of bladder tumor in non–muscle-invasive bladder cancer: Clinical outcomes and molecular predictors from over 3 years of extended follow-up in a phase II trial. Investigative and Clinical Urology. https://doi.org/10.4111/icu.20260135

Vancouver

Lee HW, Song G, Lee HH, Jung EH, Kim SY, Kim H, et al. Intravesical mitomycin-C administered immediately before transurethral resection of bladder tumor in non–muscle-invasive bladder cancer: Clinical outcomes and molecular predictors from over 3 years of extended follow-up in a phase II trial. Investigative and Clinical Urology. 2026. doi:10.4111/icu.20260135

BibTeX
@article{Lee2026,
  author = {Lee, Hye Won and Song, Geehyun and Lee, Hyung Ho and Jung, Eui Hyun and Kim, Seo-Young and Kim, Hanbyeol and Park, Weon Seo and Kwon, Joonha and Seo, Ho Kyung},
  title = {Intravesical mitomycin-C administered immediately before transurethral resection of bladder tumor in non–muscle-invasive bladder cancer: Clinical outcomes and molecular predictors from over 3 years of extended follow-up in a phase II trial},
  journal = {Investigative and Clinical Urology},
  year = {2026},
  doi = {10.4111/icu.20260135}
}
Kostenlos starten →